This pipeline analysis report provides detailed insights into the clinical trials landscape of the gene therapy molecules for age-related macular degeneration in the development and pre-clinical stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, and target.
Overview of the gene therapy pipeline for age-related macular degeneration
It has been observed that age-related macular degeneration (AMD) is one of the major causes for vision loss and is characterized by the formation of a blurred area near the center of vision, a condition that mostly affects the geriatric population. According to the CDC, almost 2 million individuals in the US suffer from AMD and by 2050, this number will reach more than 5 million. This will subsequently demand the need for the development of innovative treatments for AMD, driving the market’s growth. The market research analysts have predicted that with the introduction of techniques such as fluorescein angiography, the global age-related macular degeneration market will register a CAGR of more than 7% by 2020. With the unavailability of FDA-approved treatment for dry AMD (dAMD) and the treatment of wet AMD (wAMD) involving the need of intravitreal injections for an indefinite period, gene therapy is emerging as the most-efficient approach for the treatment of age-related macular degeneration (AMD).
According to this pipeline analysis report, most of the gene therapy molecules in the pipeline are being developed for wet AMD (wAMD). Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of gene therapy molecules for the treatment of AMD. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the gene therapy molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are
- RetroSense Therapeutics
Therapeutic assessment of the gene therapy pipeline for AMD by route of administration
The intravitreal route of administration (ROA) involves the application of the drug directly onto the vitreous fluid and in the subretinal technique, the molecules are applied to the subretinal space, which will have a more direct effect on the target cells.
Therapeutic assessment of the gene therapy pipeline for AMD by therapy
- Combination therapy
According to this pipeline analysis report, all the molecules that are currently in the gene therapy pipeline for age-related macular degeneration are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the different stages of the pipeline molecules under investigation?
- What are the gene therapy molecules in the various development stages for age-related macular degeneration?
- What are the companies that are currently involved in the development of gene therapy molecules for age-related macular degeneration?
- What are the molecules discontinued from development?
- What are the major regulatory authorities approving drugs in various regions?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
- Gene therapy for AMD: An insight
PART 07: COMPARATIVE ANALYSIS
- Discovery stage molecules
- Pre-clinical stage molecules
- Early-stage (Phase I) molecules
- Inactive and discontinued molecules
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
- Active companies: Category and parameters
- List of abbreviations
Exhibit 01: Drug approval process by US FDA
Exhibit 02: Pipeline landscape
Exhibit 03: Pipeline molecules by vendors
Exhibit 04: Pipeline molecules by numbers
Exhibit 05: Pipeline molecules by percentage
Exhibit 06: Overview: Gene therapy for wAMD
Exhibit 07: Overview: GS030
Exhibit 08: Overview: ADVM-022/ADVM-032
Exhibit 09: Overview: Gene therapy for dAMD
Exhibit 10: Overview: A005
Exhibit 11: Overview: A006
Exhibit 12: Overview: RST-001
Exhibit 13: Overview: CERE-120
Exhibit 14: Overview: CERE-140
Exhibit 15: Overview: OXB-201
Exhibit 16: Clinical trials description of OXB-201
Exhibit 17: Overview: RGX-314
Exhibit 18: Clinical trials description of RGX-314
Exhibit 19: Inactive and discontinued molecules by numbers
Exhibit 20: Inactive and discontinued molecules
Exhibit 21: Analysis by disease type
Exhibit 22: Overview of indication
Exhibit 23: Assessment by monotherapy products by stagewise
Exhibit 24: Assessment by RoA
Exhibit 25: Segmentation of pipeline by stage and RoA
Exhibit 26: Assessment by target
Exhibit 27: Vendor landscape
Exhibit 28: Segmentation of companies
Exhibit 29: Overview: Adverum
Exhibit 30: Overview: AGTC
Exhibit 31: Overview: Ceregene
Exhibit 32: Overview: Gemini Therapeutics
Exhibit 33: Overview: Gensight Biologics
Exhibit 34: Overview: MeiraGTx
Exhibit 35: Overview: Oxford BioMedica
Exhibit 36: Overview: REGENXBIO
Exhibit 37: Overview: RetroSense Therapeutics